Free Trial

ESSA Pharma (EPIX) Competitors

ESSA Pharma logo
$1.74 +0.04 (+2.06%)
As of 07/3/2025 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EPIX vs. LFCR, AARD, OLMA, LIMN, OCGN, ZYBT, GOSS, GLUE, CRVS, and RNAC

Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Lifecore Biomedical (LFCR), Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Liminatus Pharma (LIMN), Ocugen (OCGN), Zhengye Biotechnology (ZYBT), Gossamer Bio (GOSS), Monte Rosa Therapeutics (GLUE), Corvus Pharmaceuticals (CRVS), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

ESSA Pharma vs. Its Competitors

Lifecore Biomedical (NASDAQ:LFCR) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

ESSA Pharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -35.90%. ESSA Pharma's return on equity of -23.48% beat Lifecore Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifecore Biomedical-35.90% -551.09% -13.89%
ESSA Pharma N/A -23.48%-22.86%

In the previous week, ESSA Pharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for ESSA Pharma and 0 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score.

Company Overall Sentiment
Lifecore Biomedical Neutral
ESSA Pharma Neutral

Lifecore Biomedical has higher revenue and earnings than ESSA Pharma. Lifecore Biomedical is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifecore Biomedical$128.26M2.32$12.01M-$1.45-5.54
ESSA PharmaN/AN/A-$28.54M-$0.63-2.75

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lifecore Biomedical has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential downside of 0.37%. ESSA Pharma has a consensus price target of $2.00, suggesting a potential upside of 15.27%. Given ESSA Pharma's higher possible upside, analysts plainly believe ESSA Pharma is more favorable than Lifecore Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
ESSA Pharma
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Lifecore Biomedical and ESSA Pharma tied by winning 7 of the 14 factors compared between the two stocks.

Get ESSA Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EPIX vs. The Competition

MetricESSA PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$77.24M$2.43B$5.53B$9.05B
Dividend YieldN/A1.78%5.24%4.03%
P/E Ratio-2.758.9827.5220.22
Price / SalesN/A682.84421.02118.64
Price / CashN/A158.5936.8958.07
Price / Book0.624.588.045.67
Net Income-$28.54M$31.34M$3.18B$249.13M
7 Day Performance0.29%3.25%2.82%3.30%
1 Month Performance1.46%6.80%3.70%5.20%
1 Year Performance-63.70%1.89%35.41%21.38%

ESSA Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EPIX
ESSA Pharma
1.3226 of 5 stars
$1.74
+2.1%
$2.00
+15.3%
-63.7%$77.24MN/A-2.7550News Coverage
LFCR
Lifecore Biomedical
1.0508 of 5 stars
$8.12
-0.9%
$8.00
-1.5%
+62.9%$300.68M$128.26M-5.60690High Trading Volume
AARD
Aardvark Therapeutics
N/A$13.52
+1.0%
$33.00
+144.1%
N/A$293.38MN/A0.0018Analyst Revision
Gap Up
OLMA
Olema Pharmaceuticals
1.7576 of 5 stars
$4.26
-7.8%
$24.50
+475.1%
-58.8%$291.47MN/A-2.1270Positive News
LIMN
Liminatus Pharma
N/A$11.15
+17.6%
N/AN/A$290.01MN/A0.00N/AGap Up
OCGN
Ocugen
1.0196 of 5 stars
$0.97
-1.4%
$6.00
+518.3%
-41.1%$283.39M$4.05M-5.1180High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.97
-9.7%
N/AN/A$281.61MN/A0.00278News Coverage
Lockup Expiration
Gap Down
GOSS
Gossamer Bio
3.7798 of 5 stars
$1.23
-1.6%
$7.33
+496.2%
+18.9%$279.58M$114.70M-5.35180
GLUE
Monte Rosa Therapeutics
1.3753 of 5 stars
$4.51
-2.0%
$15.33
+240.0%
+29.7%$277.41M$75.62M56.3890News Coverage
CRVS
Corvus Pharmaceuticals
2.4882 of 5 stars
$4.00
+2.8%
$15.00
+275.0%
+121.1%$272.68MN/A-4.0830Positive News
Insider Trade
RNAC
Cartesian Therapeutics
1.4476 of 5 stars
$10.39
-2.7%
$41.25
+297.0%
-36.6%$269.66M$34.17M-0.2064

Related Companies and Tools


This page (NASDAQ:EPIX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners